1 |
Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in korean men and women. JAMA 2005;293(2):194-202.
DOI
|
2 |
Hsu IR, Kim SP, Kabir M, Bergman RN. Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 2007;86(3):867S-71S.
DOI
|
3 |
Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254-8.
DOI
|
4 |
Chen YC, Kok VC, Chien CH, Horng JT, Tsai JJ. Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: A cohort study using metformin as the comparator. Ther Clin Risk Manag 2015;11:1315-23.
DOI
|
5 |
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330(7503):1304-5.
DOI
|
6 |
Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009;32(9):1620-5.
DOI
|
7 |
Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study. Diabetes Care 2012;35(1):119-24.
DOI
|
8 |
Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: A meta-analysis using primary data of published studies. Metab Clin Exp 2013;62(7):922-34.
DOI
|
9 |
Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310(5754):1642-6.
DOI
|
10 |
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017;60(9):1577-85.
DOI
|
11 |
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009;16(4):1103-23.
DOI
|
12 |
Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA 2015;112(6):1809-14.
DOI
|
13 |
Del Barco S, Vazquez-Martin A, Cufi S, et al. Metformin: Multi-faceted protection against cancer. Oncotarget 2011;2(12):896-917.
DOI
|
14 |
Suissa S and Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 2012;35(12):2665-73.
DOI
|
15 |
Chae YK, Arya A, Malecek MK, et al. Repurposing metformin for cancer treatment: Current clinical studies. Oncotarget 2016;7(26):40767-80.
DOI
|
16 |
Bodmer M, Becker C, Jick SS, Meier CR. Metformin does not alter the risk of lung cancer: A case-control analysis. Lung Cancer 2012;78(2):133-7.
DOI
|
17 |
Zhang Z, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: A systematic review and meta-analysis. Am J Epidemiol 2014;180(1):11-4.
DOI
|
18 |
Zhang Z, Zheng Z, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: A systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism 2012;97(7):2347-53.
DOI
|
19 |
Valent F. Diabetes mellitus and cancer of the digestive organs: An italian population-based cohort study. J Diabetes Complications 2015;29(8):1056-61.
DOI
|
20 |
Lee M, Hsu C, Wahlqvist ML, Tsai H, Chang Y, Huang Y. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11(1):20.
DOI
|
21 |
Tseng CH. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging (Albany NY) 2016;8(8):1636-49.
DOI
|